Novavax

NOVAVAX INC

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

biotech shutter

Analyst Color

Biotech

News

Health Care

Analyst Ratings

General

NVAX

Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.

Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst

Pfizer And Moderna Stocks

Rumors

Novavax&#39;s COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.

FDA Delays Full Approval Decision On Novavax&#39;s COVID-19 Vaccine (UPDATED)

Moderna_COVID-19_vaccine_(2021)_G

Movers

MRNA

Vaccine stocks are trading lower Monday following a shakeup at the U.S. Food and Drug Administration.

Moderna, Novavax Shares Are Tumbling Monday: What&#39;s Going On?

Novavax Inc

Press Releases

Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza

Contracts

Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone

Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

Earnings

Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Novavax to Participate in Upcoming March Investor Conferences

Novavax Announces Changes to Board of Directors

CAPC

Ardelyx

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Chimerix

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dyne Therapeutics

89bio

Geron

GRAIL

IDEAYA Biosciences

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

HC Wainwright & Co.

Jefferies

B. Riley Securities

JP Morgan

B of A Securities

Comments

Novavax

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga